- Home
- EQR vs BNTX Comparison
EQR vs BNTX Comparison
Compare EQR & BNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQR
- BNTX
- Stock Information
- Founded
- EQR 1993
- BNTX 2008
- Country
- EQR United States
- BNTX Germany
- Employees
- EQR N/A
- BNTX N/A
- Industry
- EQR Real Estate Investment Trusts
- BNTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EQR Real Estate
- BNTX Health Care
- Exchange
- EQR Nasdaq
- BNTX Nasdaq
- Market Cap
- EQR 26.7B
- BNTX 25.0B
- IPO Year
- EQR 1993
- BNTX 2019
- Fundamental
- Price
- EQR $66.78
- BNTX $106.47
- Analyst Decision
- EQR Buy
- BNTX Strong Buy
- Analyst Count
- EQR 15
- BNTX 18
- Target Price
- EQR $79.00
- BNTX $141.55
- AVG Volume (30 Days)
- EQR 1.9M
- BNTX 1.1M
- Earning Date
- EQR 07-28-2025
- BNTX 08-04-2025
- Dividend Yield
- EQR 4.11%
- BNTX N/A
- EPS Growth
- EQR 8.50
- BNTX N/A
- EPS
- EQR 2.62
- BNTX N/A
- Revenue
- EQR $3,010,100,000.00
- BNTX $2,968,331,171.00
- Revenue This Year
- EQR $5.13
- BNTX N/A
- Revenue Next Year
- EQR $4.28
- BNTX $10.68
- P/E Ratio
- EQR $25.74
- BNTX N/A
- Revenue Growth
- EQR 3.81
- BNTX 0.61
- 52 Week Low
- EQR $59.41
- BNTX $76.53
- 52 Week High
- EQR $78.84
- BNTX $131.49
- Technical
- Relative Strength Index (RSI)
- EQR 34.93
- BNTX 53.76
- Support Level
- EQR $65.19
- BNTX $102.57
- Resistance Level
- EQR $69.87
- BNTX $107.51
- Average True Range (ATR)
- EQR 1.21
- BNTX 2.83
- MACD
- EQR -0.36
- BNTX -0.25
- Stochastic Oscillator
- EQR 15.54
- BNTX 56.58
About EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 312 apartment communities with over 84,000 units and is developing two additional properties with 655 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.
About BNTX BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.